Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 182: 108374, 2021 01.
Article in English | MEDLINE | ID: mdl-33115642

ABSTRACT

Synthetic cannabinoids were introduced into recreational drug culture in 2008 and quickly became one of the most commonly abused drugs in the United States. The neurobiological consequences resulting from synthetic cannabinoid repeated exposure remain poorly understood. It is possible that a blunted dopamine (DA) response may lead drug users to consume larger quantities to compensate for this form of neurochemical tolerance. Because the endogenous cannabinoid and opioid systems exhibit considerable cross-talk and cross-tolerance frequently develops following repeated exposure to either opioids or cannabinoids, there is interest in investigating whether a history of synthetic cannabinoid exposure influences the ability of heroin to increase DA release. To test the effects of chronic cannabinoid exposure on cannabinoid- and heroin-evoked DA release, male adult rats were treated with either vehicle or a synthetic cannabinoid (WIN55-212-2; WIN) using an intravenous (IV) dose escalation regimen (0.2-0.8 mg/kg IV over 9 treatments). As predicted, WIN-treated rats showed a rightward shift in the dose-response relationship across all behavioral/physiological measures when compared to vehicle-treated controls. Then, using fast-scan cyclic voltammetry to measure changes in the frequency of transient DA events in the nucleus accumbens shell of awake and freely-moving rats, it was observed that the DA releasing effects of both WIN and heroin were significantly reduced in male rats with a pharmacological history of cannabinoid exposure. These results demonstrate that repeated exposure to the synthetic cannabinoid WIN can produce tolerance to its DA releasing effects and cross-tolerance to the DA releasing effects of heroin.


Subject(s)
Analgesics, Opioid/pharmacology , Benzoxazines/pharmacology , Cannabinoids/administration & dosage , Dopamine/metabolism , Drug Tolerance/physiology , Heroin/pharmacology , Morpholines/pharmacology , Naphthalenes/pharmacology , Age Factors , Analgesics , Animals , Dose-Response Relationship, Drug , Drug Administration Schedule , Male , Pain Measurement/drug effects , Pain Measurement/methods , Rats , Rats, Long-Evans
2.
Neuroscientist ; 22(6): 593-603, 2016 12.
Article in English | MEDLINE | ID: mdl-26338491

ABSTRACT

The prefrontal cortex is the center of cognitive control. Processing in prefrontal cortical circuits enables us to direct attention to behaviorally relevant events; to memorize, structure, and categorize information; and to learn new concepts. The prefrontal cortex receives strong projections from midbrain neurons that use dopamine as a transmitter. In this article, we review the crucial role dopamine plays as a modulator of prefrontal cognitive functions, in the primate brain in particular. Following a summary of the anatomy and physiology of the midbrain dopamine system, we focus on recent studies that investigated dopaminergic effects in prefrontal cortex at the cellular level. We then discuss how unregulated prefrontal dopamine signaling could contribute to major disorders of cognition. The studies highlighted in this review demonstrate the powerful influence dopamine exerts on the mind.


Subject(s)
Attention/physiology , Cognition/physiology , Dopamine/metabolism , Prefrontal Cortex/physiology , Animals , Humans , Models, Neurological , Neurons/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...